QURE uniQure N.V. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
06:58
Jul 26
Jul 26
Author frames QURE as an ongoing catalyst-driven biotech position; the word "remains" confirms continued holding with an event-driven thesis.
MED
09:11
Jul 19
Jul 19
Author maintains QURE as a core holding, explicitly framing it as a catalyst-driven biotech position with an expected near-term event.
MED
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
05:14
Jun 18
Jun 18
UniQure shares surged 78% after the company announced it was seeking FDA approval for its Huntington's disease gene therapy, following unusual options activity.
14:07
Jun 17
Jun 17
Author contrasts QURE favorably against NTLA — QURE holds a unique, first-and-only position in a large, severe, fatal indication with no competitive crowding.
MED
11:13
Jun 17
Jun 17
Author reflects on a prior bullish call on biotech bottom and specific catalysts like QURE approval and ABVX acquisition, but the tweet is a retrospective check-in rather than a fresh forward position.
LOW
11:07
Jun 17
Jun 17
The tweet links to an external article about QURE without providing any personal position or directional view from the author.
LOW
11:05
Jun 17
Jun 17
Reports FDA communication that 3-year Phase I/II data may support BLA for accelerated approval of AMT-130 in Huntington's disease; speaker does not state a personal directional view.
MED
17:29
Jun 14
Jun 14
Inquiry about continued holding in $QURE; no directional view or commitment from speaker.
LOW
22:31
Jun 11
Jun 11
Author asks for update on QURE and mentions a potential rotation from HUBC, but no committed directional view or catalyst.
LOW
21:38
May 13
May 13
The author lists a crowd-sourced basket of stocks already up 2-6 times but expresses no personal forward-looking directional view, merely endorsing followers' conviction with a vague "so do I" that lacks a specific trade thesis.
HIGH
16:04
Jan 11
Jan 11
Author extends bearish gene-therapy thesis to QURE, citing unpredictable FDA regulatory risk as a structural overhang analogous to the NTLA safety/commercial impairment thesis.
MED
About QURE Analyst Coverage
Buzzberg tracks QURE (uniQure N.V.) across 6 sources. 3 bullish vs 1 bearish calls from 6 analysts. Sentiment: predominantly bullish (15%). 13 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: mkfilko, seedy19tron, unusual_whales.